Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Sep;58(9):5047-53.
doi: 10.1128/AAC.02830-14. Epub 2014 Jun 9.

Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A

S U Nayak  1 , J M Griffiss  2 , R McKenzie  1 , E J Fuchs  1 , R A Jurao  1 , A T An  1 , A Ahene  3 , M Tomic  3 , C W Hendrix  1 , J M Zenilman  4
Affiliations
Clinical Trial

Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A

S U Nayak et al. Antimicrob Agents Chemother. 2014 Sep.

Abstract

Botulinum neurotoxin A is a category A bioterrorism agent. Current antitoxin therapies are scarce and produce adverse reactions. XOMA 3AB consists of 3 IgG1 monoclonal antibodies (MAbs), each with a distinct human or humanized variable region, which bind to distinct epitopes on botulinum neurotoxin serotype A. This first-in-human study evaluated the safety and pharmacokinetics (PK) of escalating doses of XOMA 3AB administered intravenously (i.v.) to healthy adults. In this double-blind placebo-controlled dose escalation study, 3 cohorts of 8 healthy subjects received a single intravenous dose of XOMA 3AB or placebo at a 3:1 ratio. Follow-up examinations included physical examinations, hematology and chemistry blood tests, electrocardiograms, and pharmacokinetics. Pharmacokinetic parameters were estimated using noncompartmental methods. There were no infusion discontinuations or hypersensitivity reactions. Two or more subjects experienced headache, hyperglycemia, or anemia; none was dose related. All adverse events (AEs) were mild to moderate except for an episode of exercise-induced elevation of a subject's creatine phosphokinase (CPK) level, unrelated to XOMA 3AB. Concentration-time plots demonstrated a peak in MAb concentrations 1 to 2 h after completion of the infusion, after which the levels declined in a biexponential decay pattern for all analytes. For each MAb, the maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve from 0 to infinity (AUCinf) increased as the dose increased. Clearance of the humanized mouse MAb was more rapid than that of the two fully human MAbs, particularly at the lowest dose. None of the MAbs was immunogenic. At the doses administered, XOMA 3AB was well tolerated. These safety findings support further investigation of XOMA 3AB as a potential agent for botulism treatment and postexposure prophylaxis. (This study has been registered at ClinicalTrials.gov under registration no. NCT01357213.).

PubMed Disclaimer

Figures

FIG 1
FIG 1
Plasma concentrations over time of Aa, Ab, and Ac monoclonal antibodies after a single i.v. infusion.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lacy DB, Stevens RC. 1999. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291:1091–1104. 10.1006/jmbi.1999.2945 - DOI - PubMed
    1. Barash JR, Arnon SS. 2014. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J. Infect. Dis. 209:183–191. 10.1093/infdis/jit449 - DOI - PubMed
    1. Centers for Disease Control and Prevention. 1998. Botulism in the United States 1899–1996. In Handbook for epidemiologists, clinicians and laboratory workers. Centers for Disease Control and Prevention, Atlanta, GA
    1. Dembek ZF, Smith LA, Rusnak JM. 2007. Botulism: cause, effects, diagnosis, clinical and laboratory identification and treatment modalities. Disaster Med. Public Health Prep. 1:122–134. 10.1097/DMP.0b013e318158c5fd - DOI - PubMed
    1. Arnon SS, Schecter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K, Working Group on Civilian Biodefense 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059–1070. 10.1001/jama.285.8.1059 - DOI - PubMed

Publication types

Substances

Associated data

  NODES
admin 2
twitter 2